Health Care·Biotechnology·$161.9B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.44 | N/A | -19.16% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $1.44 | N/A | -19.16% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concerns about current market conditions impacting results. They remain focused on long-term growth strategies.
Management highlighted challenges in the market affecting performance.
They emphasized a focus on long-term strategies despite short-term hurdles.
The earnings report indicates that Gilead Sciences faced challenges in the fourth quarter, leading to a notable miss on EPS. The lack of revenue data and guidance may leave investors uncertain about the company's near-term prospects. The stock reaction is not available, but the defensive tone from management suggests caution moving forward.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
NOVO-NORDISK A S ADR
Feb 1, 2019